Exelixis Company Profile (NASDAQ:EXEL)

About Exelixis

Exelixis logoExelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: EXEL
  • CUSIP: 30161Q10
Key Metrics:
  • Previous Close: $10.98
  • 50 Day Moving Average: $9.70
  • 200 Day Moving Average: $6.38
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -47.74
  • P/E Growth: 0.64
  • Market Cap: $2.53B
  • Outstanding Shares: 230,325,000
  • Beta: 2.09
Additional Links:
Companies Related to Exelixis:

Analyst Ratings

Consensus Ratings for Exelixis (NASDAQ:EXEL) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $10.67 (2.85% downside)

Analysts' Ratings History for Exelixis (NASDAQ:EXEL)
Show:
DateFirmActionRatingPrice TargetDetails
8/29/2016Leerink SwannReiterated RatingBuy$12.00View Rating Details
8/10/2016Cowen and CompanyReiterated RatingBuyView Rating Details
8/4/2016Piper Jaffray Cos.Reiterated RatingNeutral$5.00 -> $8.00View Rating Details
8/4/2016Stifel NicolausBoost Price TargetBuy$10.00 -> $12.00View Rating Details
1/13/2016William BlairReiterated RatingBuyView Rating Details
(Data available from 8/29/2014 forward)

Earnings

Earnings History for Exelixis (NASDAQ:EXEL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016        
8/3/2016Q216($0.27)($0.16)$16.76 million$36.25 millionViewListenView Earnings Details
5/4/2016Q116($0.25)($0.27)$9.11 million$15.40 millionViewListenView Earnings Details
2/29/2016Q415($0.22)($0.19)$8.16 million$9.94 millionViewListenView Earnings Details
11/10/2015Q315($0.20)($0.22)$9.08 million$9.85 millionViewListenView Earnings Details
8/11/2015Q215($0.21)($0.22)$8.69 million$8.00 millionViewListenView Earnings Details
4/30/2015Q115($0.24)($0.18)$8.08 million$9.40 millionViewListenView Earnings Details
2/24/2015Q414($0.31)($0.30)$7.50 million$7.35 millionViewListenView Earnings Details
11/4/2014Q314($0.37)($0.32)$6.77 million$6.30 millionViewListenView Earnings Details
7/31/2014Q214($0.39)($0.38)$5.66 million$6.56 millionViewListenView Earnings Details
5/1/2014Q114($0.37)($0.39)$6.11 million$4.90 millionViewListenView Earnings Details
2/20/2014Q413($0.38)($0.38)$5.71 million$4.34 millionViewListenView Earnings Details
10/30/2013Q313($0.37)($0.36)$5.55 million$5.50 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.30)($0.34)$6.55 million$11.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.29)($0.24)$5.33 million$9.70 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.24)($0.28)$9.46 million$7.80 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.20)$9.22 million$13.30 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.25)ViewN/AView Earnings Details
5/3/2012($0.19)($0.18)ViewN/AView Earnings Details
10/27/2011$0.57$0.60ViewN/AView Earnings Details
8/4/2011($0.17)($0.16)ViewN/AView Earnings Details
5/3/2011($0.19)($0.24)ViewN/AView Earnings Details
2/22/2011($0.21)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Exelixis (NASDAQ:EXEL)
Current Year EPS Consensus Estimate: $-0.71 EPS
Next Year EPS Consensus Estimate: $-0.23 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.27)($0.24)($0.26)
Q2 20162($0.29)($0.28)($0.29)
Q3 20162($0.17)($0.17)($0.17)
Q4 20162($0.12)($0.11)($0.12)
Q1 20171($0.10)($0.10)($0.10)
Q2 20171($0.11)($0.11)($0.11)
Q3 20171($0.08)($0.08)($0.08)
Q4 20171($0.05)($0.05)($0.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Exelixis (NASDAQ:EXEL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Exelixis (NASDAQ:EXEL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/4/2016Gisela SchwabInsiderSell42,338$11.00$465,718.00View SEC Filing  
5/11/2016Lance WillseyDirectorBuy60,000$4.97$298,200.00View SEC Filing  
5/9/2016Lance WillseyDirectorBuy40,000$4.97$198,800.00View SEC Filing  
12/11/2015Lance WillseyDirectorBuy100,000$4.89$489,000.00View SEC Filing  
10/16/2015Peter LambEVPSell51,549$5.80$298,984.20View SEC Filing  
10/13/2015Peter LambEVPSell600$5.80$3,480.00View SEC Filing  
10/12/2015Peter LambEVPSell300,276$5.84$1,753,611.84View SEC Filing  
9/17/2014Vincent T MarchesiDirectorBuy20,000$1.71$34,200.00View SEC Filing  
8/29/2013Lance WillseyDirectorBuy10,000$5.15$51,500.00View SEC Filing  
12/20/2012Vincent T MarchesiDirectorBuy4,000$4.68$18,720.00View SEC Filing  
12/19/2012Vincent T MarchesiDirectorBuy6,000$4.72$28,320.00View SEC Filing  
12/10/2012Gisela SchwabEVPBuy25,000$4.39$109,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Exelixis (NASDAQ:EXEL)
DateHeadline
finance.yahoo.com logoWhy Exelixis (EXEL) Could Be Positioned for a Surge (NASDAQ:EXEL)
finance.yahoo.com - August 26 at 4:49 PM
4-traders.com logoExelixis : Announces Redemption of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019 (NASDAQ:EXEL)
www.4-traders.com - August 26 at 5:40 AM
reuters.com logoBRIEF-Exelixis announces redemption of remaining 4.25 convertible senior subordinated notes (NASDAQ:EXEL)
www.reuters.com - August 25 at 9:55 AM
News IconExelixis, Inc.'s (EXEL): Stock under Review - Hot Stocks Point (NASDAQ:EXEL)
www.hotstockspoint.com - August 24 at 4:52 PM
publicnow.com logoExelixis Announces Redemption of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019 (NASDAQ:EXEL)
www.publicnow.com - August 24 at 4:52 PM
forbes.com logoMobileye And Three More Stocks Breaking Out (NASDAQ:EXEL)
www.forbes.com - August 24 at 4:52 PM
thestreet.com logo4 Biotech Stock Charts You Must See (NASDAQ:EXEL)
www.thestreet.com - August 23 at 5:01 PM
streetinsider.com logoExelixis (EXEL) Enters Conv. Subordinated Notes Exchange Offer (NASDAQ:EXEL)
www.streetinsider.com - August 22 at 5:00 PM
capitalcube.com logoETF’s with exposure to Exelixis, Inc. : August 22, 2016 (NASDAQ:EXEL)
www.capitalcube.com - August 22 at 5:00 PM
News IconBiotech news that matter for investors: Exelixis, Inc. (NASDAQ:EXEL), Rock Creek Pharmaceuticals, Inc. (OTC:RCPI) - The Voice Registrar (NASDAQ:EXEL)
voiceregistrar.com - August 22 at 9:36 AM
biz.yahoo.com logoEXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:EXEL)
biz.yahoo.com - August 22 at 9:36 AM
feeds.reuters.com logoBRIEF-Exelixis says entered privately negotiated exchange agreements with certain holders (NASDAQ:EXEL)
feeds.reuters.com - August 22 at 9:10 AM
investornewswire.com logoWill Exelixis, Inc. (NASDAQ:EXEL) Hit $12 Price Target? - Investor Newswire (NASDAQ:EXEL)
www.investornewswire.com - August 21 at 9:26 AM
smarteranalyst.com logoLeerink Analyst Positive on Exelixis, Inc. Following Management Luncheon - Smarter Analyst (NASDAQ:EXEL)
www.smarteranalyst.com - August 20 at 9:09 AM
nasdaq.com logoEXEL Crosses Above Average Analyst Target (NASDAQ:EXEL)
www.nasdaq.com - August 19 at 4:52 PM
smarteranalyst.com logoLeerink Analyst Positive on Exelixis, Inc. Following Management Luncheon (NASDAQ:EXEL)
www.smarteranalyst.com - August 19 at 4:52 PM
investing.com logo4 Stocks To Watch: EXAS, EXEL, PBYI, SHOP (NASDAQ:EXEL)
www.investing.com - August 19 at 6:32 AM
News IconBiotech news that matter for investors: Exelixis, Inc. (NASDAQ:EXEL), Heat Biologics, Inc. (NASDAQ:HTBX) - The Voice Registrar (NASDAQ:EXEL)
voiceregistrar.com - August 18 at 4:56 PM
News IconAnalysts Valuations For Two Stocks: Allegheny Technologies ... - The Voice Registrar (NASDAQ:EXEL)
voiceregistrar.com - August 17 at 5:40 AM
News IconTrading the Biotech News: Exelixis, Inc. (NASDAQ:EXEL), MannKind ... - The Voice Registrar (NASDAQ:EXEL)
voiceregistrar.com - August 17 at 5:40 AM
News IconTrending Biotechnology Stocks Review: Amgen, Inc. (NASDAQ:AMGN), Exelixis, Inc. (NASDAQ:EXEL) - Post Registrar (NASDAQ:EXEL)
postregistrar.com - August 16 at 5:01 PM
News IconExelixis, Inc. (NASDAQ:EXEL) Near to Lift Curtain on September ... - The Voice Registrar (NASDAQ:EXEL)
voiceregistrar.com - August 16 at 8:13 AM
News IconAnalyst rating and Activity: Exelixis, Inc. (NASDAQ:EXEL) - The Voice Registrar (NASDAQ:EXEL)
voiceregistrar.com - August 12 at 5:37 AM
capitalcube.com logoETF’s with exposure to Exelixis, Inc. : August 11, 2016 (NASDAQ:EXEL)
www.capitalcube.com - August 11 at 5:05 PM
finance.yahoo.com logoEXELIXIS, INC. Financials (NASDAQ:EXEL)
finance.yahoo.com - August 11 at 5:05 PM
News IconBiotech Stocks To Put On Your Watch List: Exelixis, Inc. (NASDAQ:EXEL), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - The Voice Registrar (NASDAQ:EXEL)
voiceregistrar.com - August 10 at 12:18 PM
seekingalpha.com logoExelixis: Raising Target To $12 Following Cabometyx's Strong Launch - Seeking Alpha (NASDAQ:EXEL)
seekingalpha.com - August 10 at 12:18 PM
capitalcube.com logoExelixis, Inc. :EXEL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:EXEL)
www.capitalcube.com - August 10 at 12:18 PM
biz.yahoo.com logoEXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities (NASDAQ:EXEL)
biz.yahoo.com - August 9 at 9:14 PM
streetupdates.com logoTake a look at Analysts Tips: Exelixis, Inc. (NASDAQ:EXEL) , Inovio ... - Street Updates (NASDAQ:EXEL)
www.streetupdates.com - August 9 at 3:38 PM
News IconHealthcare Names On Frontline: Great Basin Scientific, Inc. (NASDAQ:GBSN), Exelixis, Inc. (NASDAQ:EXEL) - TWN (NASDAQ:EXEL)
thewellesleysnews.com - August 9 at 6:16 AM
streetupdates.com logoNotable Analysts Recommendation to Monitor: Exelixis, Inc ... - Street Updates (NASDAQ:EXEL)
www.streetupdates.com - August 9 at 6:16 AM
fool.com logo2 Factors Pushing Exelixis, Inc. Up by 18% in July - Motley Fool (NASDAQ:EXEL)
www.fool.com - August 9 at 6:16 AM
fool.com logo2 Factors Pushing Exelixis, Inc. Up by 18% in July (NASDAQ:EXEL)
www.fool.com - August 8 at 2:26 PM
News IconAnalysts Rating to Track: Exelixis, Inc. (NASDAQ:EXEL) – Voice ... - The Voice Registrar (NASDAQ:EXEL)
voiceregistrar.com - August 5 at 5:00 PM
News IconAnalyst Research and Recommendations: Exelixis, Inc. (NASDAQ:EXEL), Sabre Corporation (NASDAQ:SABR) - TWN (NASDAQ:EXEL)
thewellesleysnews.com - August 5 at 5:00 PM
equities.com logoExelixis Inc. (EXEL) Jumps 17.89% on August 04 - Equities.com (NASDAQ:EXEL)
www.equities.com - August 5 at 6:37 AM
News IconCorrection: Earns-Exelixis story (NASDAQ:EXEL)
www.miamiherald.com - August 4 at 10:43 PM
smarteranalyst.com logoPiper Jaffray Analyst Reiterates Neutral Rating on Exelixis, Inc. (EXEL) (NASDAQ:EXEL)
www.smarteranalyst.com - August 4 at 10:43 PM
streetupdates.com logoReview of Analysts Ranking: Exelixis, Inc. (NASDAQ:EXEL) , IDEXX Laboratories, Inc. (NASDAQ:IDXX) - Street Updates (NASDAQ:EXEL)
www.streetupdates.com - August 4 at 5:14 PM
News IconPre Session Movers- Exelixis, Inc. (NASDAQ:EXEL), iPass Inc. (NASDAQ:IPAS), Peapack-Gladstone Financial ... - Seneca Globe (NASDAQ:EXEL)
www.senecaglobe.com - August 4 at 5:14 PM
News IconBreaking Down Exelixis, Inc.'s Drug Launch - Madison.com (NASDAQ:EXEL)
host.madison.com - August 4 at 5:14 PM
thestreet.com logoWhy Exelixis (EXEL) Stock Is Soaring Today (NASDAQ:EXEL)
www.thestreet.com - August 4 at 5:14 PM
finance.yahoo.com logoExelixis (EXEL) Posts Narrower Loss in Q2, Beats on Revenues (NASDAQ:EXEL)
finance.yahoo.com - August 4 at 5:14 PM
fool.com logoBreaking Down Exelixis, Inc.'s Drug Launch (NASDAQ:EXEL)
www.fool.com - August 4 at 2:34 PM
seekingalpha.com logoExelixis beats by $0.11, beats on revenue - Seeking Alpha (NASDAQ:EXEL)
seekingalpha.com - August 4 at 6:25 AM
seekingalpha.com logoExelixis +7.2% to five-year high after healthy Q2 beat - Seeking Alpha (NASDAQ:EXEL)
seekingalpha.com - August 4 at 6:25 AM
finance.yahoo.com logoEdited Transcript of EXEL earnings conference call or presentation 3-Aug-16 9:00pm GMT (NASDAQ:EXEL)
finance.yahoo.com - August 4 at 6:25 AM
sg.finance.yahoo.com logoExelixis reports 2Q loss (NASDAQ:EXEL)
sg.finance.yahoo.com - August 3 at 10:37 PM
seekingalpha.com logoExelixis +7.2% to five-year high after healthy Q2 beat (NASDAQ:EXEL)
seekingalpha.com - August 3 at 7:01 PM

Social

Exelixis (NASDAQ:EXEL) Chart for Monday, August, 29, 2016


Last Updated on 8/29/2016 by MarketBeat.com Staff